Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price & Analysis
Ginkgo Bioworks Holdings, Inc. (DNA) fell 0.14% to USD 6.94 as of September 8, 2026 at 23:42 UTC, according to Nexqual real-time market data.
DNA last closed at USD 6.95; the session ranged USD 6.75–7.05 on volume of 1,076,147 shares. Market capitalization is $467.34M, with a 52-week range of USD 5.37–17.58 (NYQ). Source: Nexqual, September 8, 2026 at 23:42 UTC.
Key Statistics (as of September 8, 2026 at 23:42 UTC)
| Price | USD 6.94 |
|---|---|
| Change | ▼ 0.14% (down) |
| Previous Close | USD 6.95 |
| Open | USD 7 |
| Day Range | USD 6.75 – 7.05 |
| 52-Week Range | USD 5.37 – 17.58 |
| Volume | 1,076,147 shares |
| Market Cap | $467.34M |
| Exchange | NYQ |
Technical Analysis (DNA)
Nexqual's technical model rates DNA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 23:42 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.06 (neutral) |
| vs SMA50 | Below (USD 8.05) |
| MACD | -0.29 (negative) |
Analyst Ratings (DNA)
Wall Street analysts rate DNA "Underperform" based on 2 analysts, with a mean price target of USD 7 (range USD 5–9), per Nexqual as of September 8, 2026 at 23:42 UTC.
| Consensus Rating | Underperform |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 7 |
| High Target | USD 9 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 0 / 1 / 2 |
Earnings (DNA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.58 |
| Revenue Estimate | $21.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.73 vs est -0.7 ▼ miss |
| 2026-03-31 | USD -1.39 vs est -1.34 ▼ miss |
| 2025-12-31 | USD -0.77 vs est -1.11 ▲ beat |
| 2025-09-30 | USD -1.45 vs est -1.24 ▼ miss |
Source: Nexqual, September 8, 2026 at 23:42 UTC.
Financials & Fundamentals (DNA)
| Total Revenue | $132.42M |
|---|---|
| Revenue Growth (YoY) | -48.50% |
| Gross Margin | +68.04% |
| Operating Margin | -284.99% |
| Profit Margin | -219.61% |
| ROE | -59.94% |
| Debt / Equity | 96.15 |
| Current Ratio | 4.57 |
| Total Cash | $302.16M |
| Total Debt | $404.11M |
| Free Cash Flow | $-72.40M |
Source: Nexqual, September 8, 2026 at 23:42 UTC.
Financial Health Score (DNA)
Nexqual rates Ginkgo Bioworks Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 23:42 UTC.
| Growth | Critical — Revenue -25% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $302M cash vs $404M debt |
| Cash Flow | Weak — FCF negative: -$72M, burning cash |
| Efficiency | Critical — ROE -60%, ROA -16.7% |
Ownership (DNA)
| Insider Ownership | +4.43% |
|---|---|
| Institutional Ownership | +73.70% |
| Shares Outstanding | 55.38M |
| Float | 49.87M |
| Short % of Float | +10.43% |
Source: Nexqual, September 8, 2026 at 23:42 UTC.
Leadership (DNA)
Ginkgo Bioworks Holdings, Inc. is led by Jason Kelly (age 44), Co-Founder, Co-COO, CEO & Director, per Nexqual as of September 8, 2026 at 23:42 UTC.
| Co-Founder, Co-COO, CEO & Director | Jason Kelly (age 44) |
|---|---|
| Co-Founder, President & Director | Reshma P. Shetty (age 44) |
| Chief Financial Officer | Steven P. Coen (age 59) |
| Co-Founder & CTO | Bartholomew Canton |
| Co-Chief Operating Officer | Jennifer Wipf |
Major Backers & Investors (DNA)
Notable institutional backers of Ginkgo Bioworks Holdings, Inc. include Viking Global, Erste Asset Management GmbH, Baillie Gifford, according to Nexqual as of September 8, 2026 at 23:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Viking Global | 6.46% |
| Erste Asset Management GmbH | 4.58% |
| Baillie Gifford | 4.32% |
| Anchorage Capital Group, LLC | 3.15% |
| Forbes, J.M. & Company | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.44% |
| Vanguard Group | 7.45% |
| State Street | 3.25% |
| Legal & General Group PLC | 3.01% |
| Geode Capital | 2.21% |
Source: Nexqual, September 8, 2026 at 23:42 UTC.
From Ginkgo Bioworks Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
- It operates through the Cell Engineering and Biosecurity segments.
- The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.
- It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMGN | Amgen Inc. | USD 393.17 | ▼ 11.47% |
| SGP | SpyGlass Pharma, Inc. | USD 28.92 | ▼ 0.24% |
| INCY | Incyte Corporation | USD 124.4 | ▼ 2.81% |
| BIIB | Biogen Inc. | USD 212.5 | ▼ 5.35% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.74 | ▲ 0.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 23:42 UTC. This page is informational and not investment advice.